Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the ...

Three-quarters of US-based researchers and graduate students are considering working abroad, according to a recent study.

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

The FDA has cleared Fujirebio Diagnostics' Lumipulse blood test, marking the first of its kind for Alzheimer's diagnosis. This test measures pTau217 and β-amyloid 1-42 proteins to detect amyloid ...

Michigan has always been a place where impossible ideas become reality. Our state is the birthplace of Ford and GM, Kellogg ...

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for ...

President and CEO Julian Adams, Ph.D., will speak at a public workshop hosted by the National Academies of Sciences, ...

The United States will revoke visas of Chinese students linked to the Chinese Communist Party or studying sensitive subjects.